Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Lutetium-177 PSMA-I&T |
| Synonyms | |
| Therapy Description |
Lutetium-177 PSMA-I&T is a radioconjugate comprising the radionuclide Lu 177 linked to a PSMA inhibitor for imaging and therapy (PSMA I&T), which potentially inhibits tumor growth (PMID: 26089548). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Lutetium-177 PSMA-I&T | 177Lu-labeled PSMA I&T|Lu-177-PSMA-I&T | Lutetium-177 PSMA-I&T is a radioconjugate comprising the radionuclide Lu 177 linked to a PSMA inhibitor for imaging and therapy (PSMA I&T), which potentially inhibits tumor growth (PMID: 26089548). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06259123 | Phase II | Lutetium-177 PSMA-I&T | Neoadjuvant PSMA-RLT in Oligometastatic PCa | Recruiting | AUT | 0 |
| NCT05383079 | Phase Ib/II | Lutetium-177 PSMA-I&T | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study (AlphaBet) | Active, not recruiting | AUS | 0 |
| NCT06343038 | Phase I | Lutetium-177 PSMA-I&T 161Tb-SibuDAB | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS) | Recruiting | CHE | 0 |
| NCT06220188 | Phase II | Lutetium-177 PSMA-I&T | PSMA-RLT in Biochemically Recurrent PCa | Recruiting | AUT | 0 |
CKB BOOST